Cell-Mediated Immunity Based Primary Prophylaxis for CMV Infection in Organ Transplant Recipients

Overview

About this study

The study will prospectively determine the clinical utility of CMV cell-mediated immunity using the Quantiferon test. The investigators will use the assay results to tailor the duration of CMV prophylaxis in solid organ transplant patients.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

Inclusion Criteria: 

  • Adult kidney, kidney-pancreas, liver transplant recipient, or heart transplant recipient 
  • CMV D+/R- patient or any R+ patient who received antithymocyte globulin induction therapy

Exclusion Criteria:

  • Unable to comply with protocol
  • Campath (Alemtuzumab) induction
  • Receiving another investigational compound for CMV treatment or prophylaxis.
  • Allergy to valganciclovir or ganciclovir
  • Receiving an investigational compound for prevention or treatment of rejection, or participating in another interventional study

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Raymund Razonable, M.D.

Contact us for the latest status

Contact information:

Brittany Price

(507)266-8725

Price.Brittany@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available